Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:administeredBy |
oral
|
| gptkbp:CASNumber |
15753-57-6
|
| gptkbp:class |
nootropic
|
| gptkbp:effect |
potential cognitive enhancement
|
| gptkbp:hasMolecularFormula |
C13H16N2O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
BZO
|
| gptkbp:isNotApprovedBy |
gptkb:FDA
|
| gptkbp:IUPACName |
benzyl-2-oxo-1-pyrrolidineacetamide
|
| gptkbp:legalStatus |
uncontrolled (in most countries)
|
| gptkbp:molecularWeight |
232.28 g/mol
|
| gptkbp:relatedTo |
piracetam
|
| gptkbp:sells |
research chemical
|
| gptkbp:structureType |
racetam
|
| gptkbp:synonym |
gptkb:benzylpiracetam
|
| gptkbp:usedFor |
cognitive enhancement
|
| gptkbp:bfsParent |
gptkb:Bolzano_Airport
|
| gptkbp:bfsLayer |
5
|